By Lexaria Bioscience Corp. on Friday, 12 October 2018
Category: Pharmaceutical - BioTech

Lexaria Bioscience continues to show success after restructuring company

viewLexaria Bioscience Corp.

() CEO Chris Bunka stopped by the Vancouver studio of Proactive Investors to talk about his companies success following the restructuring that gave Lexaria four separate divisions including nicotine, pharmaceuticals, hemp and cannabis.

Bunka also talked about what his vision for the company is heading in to 2019.
 

CSE:LXX

Market: CSE
Market Cap: $52.47 m
Follow

View company profile

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Most read

Buds & Duds: Cannabis stocks hold steady; Lexaria rises on amended agreement...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, inched 0.2% higher at 122.9 points. Elsewhere, the OTCQX Cannabis index lost 0.2% to 489.3 points. Buds today are Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), Curaleaf Holdings Inc...

1 week, 5 days ago

2 min read

Related Posts